about
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disordersSelf-monitoring and psychoeducation in bipolar patients with a smart-phone application (SIMPLe) project: design, development and studies protocolsPsychoeducation in bipolar disorder with a SIMPLe smartphone application: Feasibility, acceptability and satisfaction.Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic reviewLower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol."Is bipolar disorder an endocrine condition?" Glucose abnormalities in bipolar disorder.Implementing psychosocial evidence-based practices in mental health: are we moving in the right direction?Age at onset versus family history and clinical outcomes in 1,665 international bipolar-I disorder patients.Overview of antidepressant treatment of bipolar depression.Stratified medicine for mental disorders.Risk factors for antidepressant-related switch to mania.Faster onset of antimanic action with haloperidol compared to second-generation antipsychotics. A meta-analysis of randomized clinical trials in acute mania.Direct comparison of tricyclic and serotonin-reuptake inhibitor antidepressants in randomized head-to-head trials in acute major depression: Systematic review and meta-analysis.The real world cost and health resource utilization associated to manic episodes: The MANACOR study.Risk factors for rapid cycling in bipolar disorder.Treatment of narcolepsy complicated by psychotic symptoms.Suicidal risk factors in bipolar I and II disorder patients.Re-analysis of the earliest controlled trials of imipramine.Tricyclic and selective serotonin-reuptake-inhibitor antidepressants compared with placebo in randomized trials for acute major depression.Morbidity in Depressive Disorders.Predictors of functional outcome after a manic episode.Making sense of DSM-5 mania with depressive features.Duration of untreated psychosis and acute remission of negative symptoms in a South American first-episode psychosis cohort.e-HCL-32: a useful, valid and user friendly tool in the screening of bipolar II disorder.Brain germinoma presenting as a first psychotic episode in an adolescent male.Declining efficacy in controlled trials of antidepressants: effects of placebo dropout.Origins of psychiatric hospitalization in medieval Spain.Bipolar depression: clinical correlates of receiving antidepressants.Predominant recurrence polarity among 928 adult international bipolar I disorder patients.Early treatment resistance in a Latin-American cohort of patients with schizophrenia.F127. GLOBAL RECOVERY IN A FIRST EPISODE PSYCHOSIS PROGRAM IN SOUTH AMERICA.S101. CLINICAL FACTORS ASSOCIATED WITH CANNABIS USE IN A CHILEAN SAMPLE OF FIRST EPISODE PSYCHOSIS PATIENTS.T222. EARLY TREATMENT RESISTANCE IN A LATIN-AMERICAN COHORT OF PATIENTS WITH SCHIZOPHRENIA.¿Debería considerarse la obesidad un factor limitante para el tratamiento con clozapina?Clozapina y agranulocitosis en España: ¿tenemos una población más segura? Seguimiento hematológico a 5 años de una cohorte de pacientes tratados con clozapinaEarly Medication Discontinuation on Long-term Recovery Outcome in First-Episode PsychosisClinical characterization of rapid cycling bipolar disorder: Association with attention deficit hyperactivity disorderHigh prevalence of metabolic alterations in Latin American patients at initial stages of psychosisImaging Social and Environmental Factors as Modulators of Brain Dysfunction: Time to Focus on Developing Non-Western Societies
P50
Q30583384-82E6D778-36C8-4979-8AE0-84219A2C6433Q33443296-7F957061-CC4A-40A8-B0E0-E60E99C72916Q33448472-767F71B7-723E-4696-8B18-87ACC062EAAFQ33878816-B8C10715-2E19-43C4-B9AD-8D3CDEBC0B3CQ34240696-46E65B45-67B5-4B4B-8948-CD1CBD1D7CF1Q34307557-7696E82B-1004-4B4A-AC1B-A5A8448FD3A4Q35323821-FA20C11E-A770-413F-B56C-D2882D265039Q35403157-00C6394C-B90D-42EF-BA21-C8AC74EBFECEQ35698752-9A6DD214-44EC-41FB-B172-954536262193Q38083305-2FA6478D-DE94-4B96-8C98-53A4BE39CD75Q38157370-50E569D7-97C7-4260-B079-484CC6D9D373Q38474943-BF56D883-644C-43C9-8F70-2FA6368AE97FQ39244259-3519B397-9C7C-4F8D-85C4-C5E1402E5AC2Q39386532-35A09B0B-2546-43F1-AB78-6951E3D84DB4Q41264436-4571C537-CBBD-4419-B3F2-FFEB6ED457DAQ41434848-8F1F45FB-3368-4418-AD7B-920F3FAC3839Q43290598-25ED5A6F-282E-441D-9556-732935DF919FQ44926849-16A9050C-674C-4DCF-9489-ECED7D93B4A7Q46986087-A297110F-0771-4BE9-AC51-4C57F3077EA6Q47694034-E2B5957B-DE7E-443F-AC34-FC9E1CD782E0Q47973002-4AE0B76B-75FB-4BD3-86FD-B55E7D347F21Q48082766-5CF45194-9491-4A30-B166-B4D85CF76C15Q48083750-E5E8F319-BDA7-420A-91E4-978396D118B0Q48148492-2BF0D2CC-7921-456A-8856-44553ADBB9CBQ48203156-914094E5-C5AD-4DEB-9DEA-95022130DED1Q48253271-DB0AB2EB-4526-4F22-B9B6-ECFF03FE5669Q48336238-D4C5F177-347D-42B4-BB98-5F7DC5619914Q48480137-5A5C8A10-294F-4D3B-8042-E28D9F1B253EQ48715901-12E12849-51B3-47F7-A499-33B69BB872EEQ48779723-45471CAE-C8BD-4EF4-8536-9E8051739459Q51412568-C4C12B37-B850-413F-A4BE-8A481FFB8735Q54983590-D5C327DD-26C2-45C7-B6E7-D803534E8961Q55004215-31F798E3-1EFD-4D51-90A1-FACC8AF81F77Q55128623-FEAF0473-BA9E-4279-A641-80622D3657D9Q57602652-2E4C41BE-008B-4DB5-8241-6A2D40CBEC23Q57602655-4D5F7EA0-D7A0-45F7-9C4B-F167B571044DQ57612290-9F98263D-38A6-48E1-A4CD-C5E69ECF5E8DQ60459749-2ABDFC68-EE16-418D-BE86-B5293A661D90Q60643073-2570676E-561A-4D53-BC21-6F137D7153F2Q60643074-23CB67B5-6639-488E-A35B-A4A3F8DB2E0E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Juan Undurraga
@ast
Juan Undurraga
@en
Juan Undurraga
@es
Juan Undurraga
@nl
Juan Undurraga
@sl
type
label
Juan Undurraga
@ast
Juan Undurraga
@en
Juan Undurraga
@es
Juan Undurraga
@nl
Juan Undurraga
@sl
altLabel
Juan P Undurraga
@en
prefLabel
Juan Undurraga
@ast
Juan Undurraga
@en
Juan Undurraga
@es
Juan Undurraga
@nl
Juan Undurraga
@sl
P1053
F-3438-2012
P106
P1153
33568392600
P1960
1-UE_kQAAAAJ
P2038
Juan_Undurraga
P21
P2798
P31
P3829
P496
0000-0001-6958-2369